Mark Petrie presents STEP trial at ESC Congress 2023
Published: 5 October 2023
This has now been published in The New England Journal of Medicine (NEJM)
Global lead Mark Petrie, multinational, multi-centre trial. Weight loss drug (GLP1- agonist) in patients with HF preserved ejection fraction. Published in NEJM. https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
In a multi-center, multinational trial led by Professor Mark Petrie from the University of Glasgow, the drug Semaglutide showed significant promise in enhancing heart health for adults with a certain type of heart ailment and obesity. Participants not only experienced weight loss and felt better, but they also showcased improved walking performance in a 6-minute test. This groundbreaking discovery was unveiled as a late-breaking trial at the European Society of Cardiology Congress in Amsterdam and has been published in The New England Journal of Medicine (NEJM). The findings suggest that Semaglutide might revolutionize the treatment of heart complications associated with obesity.
First published: 5 October 2023